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ABSTRACT
Progressive accumulation of speciﬁc misfolded protein is
a deﬁning feature of amyotrophic lateral sclerosis (ALS),
similarly seen in Alzheimer disease, Parkinson disease,
Huntington disease and CreutzfeldteJakob disease. The
intercellular transfer of inclusions made of tau,
a-synuclein and huntingtin has been demonstrated,
revealing the existence of mechanisms reminiscent of
those by which prions spread through the nervous
system. Evidence for such a prion-like propagation
mechanism has now spread to the major misfolded
proteins, superoxide dismutase 1 (SOD1) and the 43 kDa
transactive response DNA binding protein (TDP-43),
implicated in ALS. The focus in this review is on what is
known about ALS progression in terms of clinical as well
as molecular aspects. Furthermore, the concept of
‘propagation’ is dissected into contiguous and
non-contiguous types, and this concept is expanded to
the severity of the focal symptom as well as its regional
spread which can be explained by cell to cell propagation
in the local neuron pool.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neuro-
degenerative disease characterised by loss of motor
neurons in the motor cortex, brainstem and spinal
cord. ALS appears to start at a focal body region and
then muscle paralysis spreads to other regions over
time. Eventually both the upper (UMNs) and lower
(LMNs) motor neurons are diffusely involved, and
the paralysis ultimately causes death due to respi-
ratory failure. Approximately 90% of all cases are
classiﬁed as sporadic ALS, deﬁned as having no
family history of the disease. The remaining cases,
designated familial ALS, are inherited in a dominant
or recessive fashion. Of the known 13 genes, muta-
tions in superoxide dismutase1 (SOD1), the 43 kDa
transactiveresponseDNAbindingprotein(TDP-43),
fusion in sarcoma, angigenin and optineurin cause
the typical ALS phenotype.
1 Cytoplasmic or nuclear
inclusions are one histopathological characteristic of
sporadic ALS. A breakthrough in understanding
sporadic ALS pathogenesis was the discovery of
TDP-43, which was identiﬁed as the major compo-
nent of the protein aggregates and of the insoluble
fraction of the brains of patients with sporadic ALS
and frontotemporal lobar degeneration.
23TDP-43
is now presumed to play an essential role in the
pathogenesis of sporadic ALS, possibly equivalent
to that of s and b amyloid in Alzheimer’s disease or
a-synuclein in Parkinson’s disease.
These pathogenic proteins or peptides have
common features: they are misfolded, they self-
aggregate and they form inclusions with cross-
b conformation and possibly toxic function. Recent
research has shown a remarkable new concept,
‘prion-like propagation,’ in non-infectious neuro-
degenerative diseases, in which pathogenic proteins
cross cellular membranes and are excreted into the
extracellular space where they are transferred to
adjacent cells; this is similar to the behaviour of the
characteristic pathogenic prion protein (PrPsc). This
intercellular transfer of pathogenic proteins leads to
the neuropathological spread of the lesion.
This article highlights the basic and clinical
aspects of the pathological progression of ALS and
discusses the possible mechanism of ‘prion-like
propagation’ in the regional spread of ALS
symptoms.
DISEASE ONSET AND PROGRESSION IN ALS
Disease onset and disease progression are thought
to have a different mechanism. Because the motor
symptoms of ALS are usually initiated in one or
two highly localised sites, the motor symptoms and
the responsible lesions always spread regionally as
the disease progresses. Many neurologists have
thought that regional spread of the symptoms is
just one aspect of disease progression in ALS
because ALS is a systemic disease that eventually
involves the entire UMN and LMN systems, and
every motor neuron in ALS ubiquitously has
a cause of disease. The most easily understood
example is familial ALS with mutations in SOD1 or
TDP-43, in which every motor neuron and glial cell
has a chromosomal genetic defect that causes
motoneuronal cell death (ﬁgure 1Aea). For the
initial onset, in sporadic as well as familial ALS,
molecular change most likely predates clinical
onset. A motor neuron becomes symptomatic
when the accumulated molecular pathology,
including increased pathogenic protein aggregates,
exceeds a certain threshold. In sporadic cases, the
multifocal hit hypothesis has a different mecha-
nism but represents a similar phenotype in which
an acquired defect in chromatin, DNA, RNA or
proteins (such as epigenetic alternation, a somatic
DNA mutation, RNA editing error or misfolding of
proteins possibly due to ageing effects or various
environmental stressors) occurs randomly in each
cell, and these defects accumulate and converge to
initiate the pathogenic process (ﬁgure 1Aeb). The
multifocal hit hypothesis (ﬁgure 1Aeb) is different
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Neurodegenerationfrom the ubiquitous change mechanism (ﬁgure 1Aea) in that
the molecular change occurs in individual cells, and unaffected
cells do not have any molecular defect. In both mechanisms, the
region of initiation may be determined by a stochastic hit but
there is a vulnerability among the motoneurons resulting in
more frequent focal involvement of the tongue and distal limb
muscles in the early stage. These two schemas shown in ﬁgure
1Aea and ﬁgure1Aeb are a possible onset mechanism of ALS
but the regional spread of the motor symptoms as a disease
progression can also be explained by just summation of the
increased number of symptomatic or hit neurons by the same
mechanism without following propagative pathology.
The concept of ‘prion-like propagation’ is the intercellular
transmission of the disease phenotype, typically considered to be
mediated by an aggregate of pathogenic proteins. Local contig-
uous spread could occur through cell to cell ‘domino-like’
propagation between neighbouring neurons in a cell autono-
mous or non-cell autonomous manner (ﬁgure 1Bea). In the case
of spinal motor neurons, this local and contiguous spread has
two vectors in the three-dimensional anatomy of motoneurons
determined by its anatomical structure: one is radial, leading to
rostral or caudal spread in the motor neuron column beyond the
spinal segment, and the other is lateral/horizontal, leading to
lateral to medial spread on one side of the anterior horn showing
progression from distal to axial muscles, and contralateral spread
within the same spinal segment showing progression to the
contralateral limb (ﬁgure 1Bea).
4
If the spread is non-contiguous, there are two possible
mechanisms: (1) anterograde trans-synaptic spread (dying
forward) or retrograde degeneration (dying back) of neural
networks (ﬁgure 1Beb, left); and (2) non-synaptic and remote
spread of a misfolded protein or toxic molecule through the
blood or CSF via exosomes, similar to the metastasis of cancer
cells (ﬁgure 1Beb, right).
5 Before regional propagation can occur,
there must be a focal lesion that develops with a molecular
mechanism that is different from that of propagation. This
initiation mechanism should include ubiquitous (ﬁgure 1Aea) or
local and multiple hit (ﬁgure 1Aeb) pathology. The contiguous
and non-contiguous propagation mechanisms are not indepen-
dent but can coexist with each other, and therefore the ﬁnal
clinical picture appears to be a complex combination of single or
multiple hits, with or without contiguous or non-contiguous
propagation.
Disease progression in ALS consists of regional spread of
motor symptoms and exacerbation of local motor symptoms,
such as a decrease in grip strength and progression of thenar
muscle atrophy. We suppose that such an exacerbation of focal
motor symptoms is also explained by the contiguous propaga-
tion mechanism. For example, the severity of hand muscle
atrophy is determined by the remaining number of motor
neurons in the lateral nuclear group of the spinal anterior horn
innervating the hand muscle after neuronal degeneration and
reinnervation of the denervated muscle ﬁbres. In this motor
neuron pool of the lateral nuclear group, neuronal degeneration
might be mediated by local cell to cell propagation of the disease
property between spinal motor neurons proximate to each other
after the seeding to a single motor neuron (ﬁgure 2). This indi-
cates that the concept of ‘propagation’ can include exacerbation
of the focal symptom as well as its regional spread.
MOLECULAR BASIS OF PROPAGATION IN ALS
Protein to protein interaction, seeded aggregation and
propagation in ALS
Familial ALS is classiﬁed into two groups, with and without
aggregation of TDP-43. The cytoplasmic mislocalisation and
aggregation of TDP-43 is now the major pathological hallmark
for sporadic ALS. Similar TDP-43 pathology is found in familial
ALS patients with mutation of optineurin, C9ORF72 and VCP,
but is not observed in those with mutation of SOD1 and FUS. In
the past 2 years, there have been cumulative data that normal
and mutant SOD1 and normal TDP-43 can undergo a similar
seeded aggregation,
6 although the pathophysiology of TDP-43
and mutant SOD1 is different and difﬁcult to discuss in the
same platform.
TDP-43 is a nuclear protein and consists of two RNA recog-
nition motifs (RRM1 and RRM2) and a proteolytic C terminal
domain, where most of the mutations are found. C terminal
fragments of TDP-43 have been identiﬁed in the cytoplasmic
inclusions of sporadic ALS patients.
2 3 TDP-43 readily aggregate
in vitro which is enhanced by ALS associated mutation,
7 and C
terminal fragments may play a critical role in TDP-43
Figure 1 Onset and regional spread mechanisms of amyotrophic
lateral sclerosis (ALS) lesion. Symptom is initiated by focal neuronal
change, the onset mechanism of which exists in every motor neuron
(Aea), or is limited to the affected neuron (Aeb). Regional spread of
symptoms may be caused by summation of the increased number of the
symptomatic or hit neurons. If the spread mechanism of ALS lesion is
explained by propagation, it is classiﬁed as local and contiguous type
(Bea) or remote and non-contiguous type (Beb). The contiguous type
propagation is based on cell to cell transfer of disease property between
the neurons proximate to each other and has a radial and horizontal
vector of spread. The non-contiguous, trans-synaptic type propagation
includes anterograde spread (dying forward) or retrograde degeneration
(dying back) of neural networks. The non-contiguous non-synaptic type
propagation includes remote transfer of the toxic molecule through blood
and CSF.
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Neurodegenerationaggregation.
89In cultured cells, misfolded forms of TDP-43 can
initiate intracellular aggregation and induce the misfolding and
subsequent aggregation of the respective native proteins.
89
What triggers TDP-43 aggregation has not been determined but
increased protein concentration due to disruption of microtu-
bule transport
9 or chronic cellular stress and defects in stress
granule disassembly
10 occurring with the ageing process may
converse to its initiation of this pathological event.
SOD1 is a stable dimer and is highly resistant to proteolytic
degradation. More than 150 point mutations have been identi-
ﬁed in SOD1, occurring at almost every position; these might
impair the stability of the protein and inﬂuence the formation of
aggregates and inclusion bodies. Both native and mutant forms
of SOD1 associated with each other, and some types of mutant
SOD1, easily form aggregates and ﬁbrils under denaturing
conditions.
5 61 1Importantly, removal of the misfolded seeds
does not stop aggregation of endogenous SOD1, indicating that
the newly formed aggregates can act as templates for the
subsequent misfolding of additional native SOD1.
11
Neuron to neuron propagation in ALS
Cellular proteins could be released from neurons via vesicle
mediated exocytosis or direct leakage through a damaged cell
membrane. Exosomes are small lipid membranous microvesicles
which are usually formed by the fusion of multivesicular bodies
with the plasma membrane. The biologically important func-
tions of exosomal release are the secretion of proteins in order to
remove unwanted proteins, the delivery of signals to other cells
and the transfer of pathogens among cells. Exosomes derived
from prion infected neuronal cell lines are efﬁcient initiators of
prion propagation in uninfected recipient cells and non-neuronal
cells. Indeed, mutant SOD1 has been proposed to be actively
secreted with neurosecretory vesicles through an abnormal
interaction with chromogranins A and B.
12 Protein aggregates
extracted from mutant SOD1 expressed cells could penetrate
into cells by macropinocytosis.
6 Importantly, a passive immu-
nisation approach based on intracerebroventricular infusion in
G93A-SOD1 mice of monoclonal antibodies speciﬁc to misfolded
forms of SOD1 succeeded in reducing the level of mutant SOD1
in the spinal cord and in prolonging the lifespan of G93A-SOD1
mice to a minor degree.
13 The exact mechanisms by which anti-
SOD1 antibodies confer protection are not yet fully understood
but the toxic effect of the excreted mutant SOD1 might be
blocked by the antibodies.
Glia to neuron propagation of toxicity in ALS
Toxic factors secreted or released from microglia and astrocytes
damage motor neurons in ALS mouse models of mutant SOD1,
which may lead to disease progression.
14 15 In vivo transplanted
glial restricted precursor cells expressing mutant human SOD1
(G93A) survive and differentiate efﬁciently into astrocytes in the
spinal cords of mice, and graft derived mutant human SOD1
astrocytes induce ubiquitination and death in host motor
neurons. Only mutant human SOD1 expressing astrocytes can
induce wild-type motor neuron death in mice.
16 Conversely,
siRNA knockdown of SOD1 in astrocytes signiﬁcantly attenu-
ates toxicity against motor neurons. In ALS, astrocytes might
induce and regulate unknown toxic factors that have a non-cell
autonomous effect on motor neurons when released.
17
CLINICAL ASPECT OF THE POSSIBILITY OF PROPAGATION
IN ALS
Focality of clinical onset and possible inﬂuencing factors
The clinical manifestations of ALS appear to start at a focal body
region and then spread to other regions over time.
18e22 The
focality of clinical onset is an important issue to discuss because
there must be an onset mechanism different from progression
pathology, whether or not cell to cell propagation underlies the
progression of ALS. At the clinical onset, almost equal propor-
tions of patients have bulbar region, upper limb or lower limb
symptoms,
19 20 with bulbar cases slightly less frequent (21e25%
of all patients).
18 21 22 Respiratory symptoms rarely occur ﬁrst.
Thus it seems that the disease can begin stochastically at any
region. However, in patients with unilateral upper limb onset,
a different frequency of onset between the right and left sides
has been reported. Ravits et al
19 reported that 34 of 100 ALS
patients had onset in the upper limbs: 24 (70.6%) in the right
and 10 (29.4%) in the left limb. In 53 ALS patients with
unilateral upper limb onset reported by Körner et al,
20 onset was
on the right in 31 (58.5%) and on the left in 22 (41.5%). This
difference between the right and left sides may relate to hand-
edness. Turner et al
23 demonstrated that, for patients with upper
limb onset, there was statistically signiﬁcant concordance
between side of onset and handedness: 97 of 151 (64%) showed
concordance overall, with 90 of 139 right-handed patients
having right-sided onset and seven of 12 left-handed patients
Figure 2 The severity of the focal symptom can be explained by local
propagation. Exacerbation of hand muscle atrophy is caused by loss of
a-motor neurons in the motor neuron pool in the spinal anterior horn
innervating the hand muscle. Such a severity of the focal symptom also
may be mediated by local cell to cell propagation between neighbouring
spinal motor neurons.
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Neurodegenerationhaving left-sided onset. In contrast, no predominance for side or
footedness has been found in patients with lower limb onset.
These ﬁndings suggest that frequent use may inﬂuence
symptom onset because the dominant hand will be used more
frequently and both legs will be almost equally used in daily
activity although a case control study revealed no association
between physical activity and the risk of developing ALS.
24 The
corticomotoneuronal organisation in the dominant and non-
dominant hand could also explain the difference in right and left
onset.
Different motor neurons may also have different vulnerabil-
ities. In a three-dimensional study of the distribution of anterior
horn cells in the cervical eighth segment of the human spinal
cord obtained at autopsy from patients with ALS, zones of focal
and patchy loss of motor neurons were identiﬁed without
consistent severity or distribution at different sectional levels.
25
According to the investigators, these ﬁndings imply that
different pools of motor neurons have varying resistance to
disease. In limb onset cases, the initial symptoms present most
commonly in distal muscles. In an analysis of 1200 patients,
Haverkamp et al
22 found that 73% of non-bulbar patients ﬁrst
exhibited symptoms in the distal portions of the limbs. In 24
autopsies of ALS patients, Tsukagoshi et al
26 found more marked
anterior horn cell loss at the eighth cervical segment, which
mainly innervates the distal hand muscles, than at the sixth
cervical segment innervating more proximal upper limb muscles.
The distal predominance in the initial symptoms does not
necessarily reﬂect only axon length dependent vulnerability
because bulbar and lower limb onset occur at the same
frequency. By using quantitative concentric needle EMG in the
early stages of ALS, de Carvalho et al
27 showed that similar
abnormalities in motor unit potentials (MUPs) were found in
paraspinal and limb muscles in the same spinal segment, both in
the sixth cervical segment and the ﬁfth lumbar segment,
although fasciculation potentials were more frequent in limb
muscles than in paraspinal muscles, and ﬁbrillations were most
frequent in the distal tibialis anterior muscle. They concluded
that the results are consistent with generalised involvement of
motor neurons in the spinal segments in the early stages of ALS
progression. The vulnerability might differ not only in motor
neurons themselves but also in the segments or sites within
a segment.
Another vulnerability may depend on axonal excitability. In
ALS, muscle wasting preferentially affects the thenar complex,
including the abductor pollicis brevis and ﬁrst dorsal inteross-
eous (FDI) muscles, compared with the hypothenar muscle
(abductor digiti minimi (ADM)). This peculiar pattern of
dissociated atrophy of the intrinsic hand muscles, termed the
‘split hand’, is nearly speciﬁc in ALS.
28 Using threshold tracking,
Bae et al
29 investigated the different membrane properties of FDI
and ADM motor axons in the same ulnar nerve at the same site
in 12 normal subjects, and demonstrated that nodal persistent
sodium conductances are more prominent in FDI axons than in
ADM axons, and therefore excitability is physiologically higher
in FDI axons. The higher excitability in FDI axons than in ADM
axons may explain the preferential involvement of FDI over
ADM in ALS.
There can also be selective vulnerability by physiological
subtypes of motoneurons. Pun et al
30 showed in two mouse
models of motoneuron disease (G93A SOD1 and G85R SOD1)
that axons of fast fatigable motoneurons were affected
synchronously, long before symptoms appeared, and fast fatigue
resistant motoneuron axons were affected at symptom onset,
whereas axons of slow motoneurons were resistant. In later
stages of human sporadic ALS, motor units with high recruit-
ment thresholds for voluntary contraction, which correspond to
the larger motoneurons, were more affected in patients with
more severely affected FDI muscles.
31
Spreading patterns of clinical manifestations
In the progression of ALS, muscle weakness regionally spreads
over time, and most UMNs and LMNs ultimately degenerate.
Spread of clinical manifestation, as well as exacerbation of focal
motor symptom, should reﬂect an increase in the number of
affected UMNs and LMNs although disturbance in a given
motoneuron can have widespread effects because of synaptic
dysfunction and loss of control at a distance in large and complex
neural networks. If cell to cell propagation of disease property
would make healthy adjacent motoneurons ill, the simplest
pattern of symptom spread should be the contiguous spread into
adjacent body regions. However, although spread is contiguous
in many ALS patients, it is sometimes non-contiguous.
Ravits et al
19 32 described, from cross sectional clinical obser-
vations, that the focal and discrete motor manifestations of ALS
present at clinical onset spread outward into contiguous body
regions. In 14 of 19 ALS nervous systems examined at autopsy,
the regional lower neuron loss within the nervous system was
graded radially away from the region of onset, suggesting
contiguous spreading of the degenerative process.
33 This
contiguous spreading pattern has also been found by other
investigators who observed cohorts of ALS patients longitudi-
nally.
20 21 Horizontal spreading along the neuroaxis occurs more
frequently than radial spreadingdthat is, the contralateral
homologous limb tends to be involved sooner than other regions
in patients with unilateral limb onset
18 20 34 although such
a directionality was not observed in one study.
35 In patients
with bulbar onset, radial spreading to the upper limbs occurred
sooner than spreading to the lower limbs in one study
21
although the difference was not statistically signiﬁcant in
another study.
18 These observations suggest that one factor
inﬂuencing the time to symptomatic spread could be distance
from the onset site. Another important feature of radial
spreading is the preferential involvement of the side ipsilateral to
the side of onsetdthat is, the leg ipsilateral to the onset arm and
the arm ipsilateral to the onset leg tend to be involved before the
contralateral limbs.
18 20 34 The underlying mechanisms of the
preferential ipsilateral spread have not yet been elucidated but
radial propagation on the ipsilateral side or the neural connec-
tions projecting to the ipsilateral cervical and lumbar spinal
motoneurons, such as the corticospinal system, might be
involved.
Spread to non-contiguous regions has also been documented
although less frequently than contiguous spreading. Fujimura-
Kiyono et al
21 showed that, among 150 patients with sporadic
ALS who underwent follow-up every 3 months, the second
region involved was a distant (non-contiguous) region in 14% of
52 patients with lower limb onset and in 29% of 32 patients
with bulbar onset. A non-contiguous spread pattern was also
found in 14.8% of 282 sporadic ALS patients investigated
retrospectively by Gargiulo-Monachelli et al
35 If ALS is a disease
whose pathological process starts as a focal ‘seed’ and then
propagates outward, the non-contiguous spreading pattern
implies that some cases start in multiple foci. This possibility is
supported by the existence of patients with clinical onset in two
regions at almost the same time. Such cases were found in 10.6%
of a cohort of 150 patients with sporadic ALS.
21 Körner et al
20
also found patients with lower limb onset who already had
bulbar involvement at disease onset. Among 19 autopsy cases of
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Neurodegenerationsporadic ALS, the loss of motoneurons was greatest in a region
different than that identiﬁed as the region of clinical onset in
two cases.
33 If only one seed is involved, one possible explana-
tion for non-contiguous spreading is anterograde trans-synaptic
propagation. Supporting this, the spread between bulbar and
spinal regions occurs preferentially in the rostralecaudal direc-
tion than caudalerostral direction
18e21 although this difference
was not obvious in one study.
35 Assessments of the cumulative
occurrence of symptomatic involvement, based on information
from serial questionnaires, demonstrated that limb symptom
accrual in 155 bulbar onset ALS patients was signiﬁcantly faster
than bulbar symptom accrual in 387 ALS patients with unilat-
eral limb onset over 6 years of follow-up.
18 On KaplaneMeier
plots, duration from bulbar onset to limb involvement was
shorter than the reverse (9 months from bulbar regions to upper
limb vs 17 months from upper limb to bulbar regions and
14 months from bulbar regions to lower limb vs 27 months from
lower limb to bulbar regions until occurrence in 50% of
patients).
21 In the monkey, it was demonstrated that some
pyramidal tract neurons in the hand and trunk areas of the
primary motor cortex have multiple axon branches projecting to
motor neuron pools in non-adjacent spinal segments.
36
However, it is important to note that the degenerative process
advances insidiously, and at least one-third of LMNs for a given
muscle were estimated to be lost before the clinical signs
manifest. Indeed, widespread abnormalities on needle electro-
myography are often found even if clinical deﬁcit is localised,
indicating that the clinical symptom manifests according to the
balance between the rate of motoneuron loss and the ability of
collateral sprouting of the remaining motoneurons which
compensates the loss. Therefore, intensive needle electromyo-
graphic studies are needed for the analysis of non-contiguous
spreading.
Relation between upper and lower motor neuron involvement
In ALS, neurodegeneration occurs in both the UMNs in the
cortex and the LMNs in the brainstem and spinal cord, and
a variable combination of UMN and LMN involvement produces
a wide variety of motor symptoms. However, the relationship
between UMN and LMN involvement is not yet fully clear.
There is ongoing discussion as to whether the UMNs or LMNs
are primarily involved (anterograde ‘dying forward’ trans-
neuronal degeneration vs retrograde ‘dying back’ degeneration)
or each is independently affected.
With regard to the onset site, Ravits et al
32 reported that
during the early stages of ALS, UMN and LMN signs were
maximal in the same peripheral body region. They speculated
that the triggering pathogenic event may be distributed by
transneuronal signalling or axonal transport, which is relevant
to the trigger and initial distribution between UMNs and LMNs.
In contrast, Körner et al
20 did not ﬁnd a correspondence of onset
regions between UMNs and LMNs in their cohort. They found
that the frequency of UMN signs was independent of the onset
region and was highest in the proximal legs at any given time
although the side of involvement corresponded with the UMN
and LMN signs. They concluded that the UMNs of the lumbar
region are more vulnerable.
With regard to regional spread, Ravits et al found that the
outward spread of UMN and LMN signs differed during disease
progression; these signs either spread to different peripheral
body regions or to the same peripheral body region but to
different extents, and there was no correlation in the severity of
UMN and LMN involvement. Other neuropathological and
neurophysiological ﬁndings seem to be consistent with the
independent involvement of UMNs and LMNs. In 12 autopsy
cases of the classical sporadic form of ALS, the pyramidal cells in
layer 5 of the tongue and foot areas of the precentral gyri were
signiﬁcantly smaller in patients than in controls but no corre-
lation was found between the mean sizes of pyramidal cells and
the numbers of surviving LMNs in the hypoglossal nucleus or in
the anterior horn of the fourth lumbar segment of the spinal
cord.
37 In 18 cases of sporadic motor neuron disease, there was
poor and negative correlation between the densities of the spinal
motor neurons in the 6the8th cervical segments and of the
corticomotoneurons in the corresponding areas.
38 In a longitu-
dinal neurophysiological study, Attarian et al
39 investigated the
changes over time of MUPs in the extensor carpi radialis and the
same single motor unit responses induced by transcranial
magnetic stimulation (TMS). They found no correlation
between UMN and LMN dysfunction in the course of disease
progression. A positive correlation was observed between macro-
MUP size and the amplitude of the excitatory responses to TMS
only in the earliest stage of the disease but this correlation
disappeared within the second year after onset. Analysis of
MUPs in the sternomastoid, which receives both contralateral
and ipsilateral corticospinal innervation, and in the trapezius,
which usually only receives contralateral innervation, revealed
symmetric changes in both muscles, and the two muscles were
equally affected, suggesting that UMNs and LMNs are inde-
pendently involved, given the characteristic asymmetry of
ALS.
40
In contrast, Körner et al
20 observed that UMN and LMN signs
predominantly spread together, rather than independently, as
Ravits et al described. In the Körner et al study, LMN involve-
ment was more distinctive than UMN involvement at disease
onset, which may support the hypothesis of initial involvement
of LMNs with a retrograde ‘dying back’ process leading to
secondary UMN degeneration.
On the other hand, the ﬁndings from a study using TMS in
patients with familial ALS with SOD1 mutations could support
the hypothesis of initial involvement of UMNs with an anter-
ograde ‘dying forward’ transneuronal process leading to
secondary LMN degeneration. Cortical hyperexcitability, which
has been shown in the early stage of sporadic ALS,
41 42 was also
found in three presymptomatic SOD1 mutation carriers, and
subsequently these three individuals developed the clinical
features of ALS.
43 Loss of inhibitory cortical interneurons is
assigned as one possible mechanism for such cortical hyperex-
citability in the early stage of the disease. These cells may be the
earliest to be involved. The increased concentration of extracel-
lular glutamate may also cause the hyperexcitability of
corticospinal neurons.
Interestingly, the split hand in ALS may have a cortical
basis.
44 A study using TMS demonstrated that the ratios of
motor evoked potentials to compound muscle action potential
were signiﬁcantly larger for the thenar complex in normal
subjects. This suggests there is a stronger corticomotoneuronal
input to these muscles, and relatively extensive cortico-
motoneuronal inputs on the thenar spinal anterior horn cells
would be associated with more glutamate release, which may
cause preferential degeneration in ALS through glutamate
induced excitotoxicity. A similar rationale might exist for the
preferential involvement of the dominant hand in ALS. A TMS
study in relation to handedness in normal subjects demonstrated
a shorter cortical silent period, reﬂecting reduced inhibitory
function, in the dominant hand.
45 The corticomotoneuronal
organisation might be relevant to the vulnerability of LMNs
rather than to the propagation of pathogenic molecular events.
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NeurodegenerationFUTURE STUDIES AND THERAPEUTIC IMPLICATIONS
OF PROPAGATION IN ALS
We do not have any concrete clinical or in vivo biological
evidence of propagation in ALS progression. Several longitudinal
and cross sectional analyses of clinical manifestations tell us
that the regional spreading pattern is contiguous in many ALS
patients, implying that propagation does contribute to
progression of this disease. On the other hand, up to 29% of
patients show a ‘skipping’ pattern of spread, such as lower limb
manifestations following bulbar onset. This is partly because
UMN and LMN signs, even if they are correlated, often progress
differently. Moreover, all of these reports were based on studies
of the involvement of broad body regions, such as the bulbar
region and upper and lower limbs, and the continuity of lesions
in spinal segments or motor cortical topography were not eval-
uated. In the spinal lesions, most neurologists do not consider
that all ALS lesions are contiguous because muscle atrophy is
frequently observed in distal hand and foot muscles.
20 22 To make
the story more complex, motoneurons have differing vulnera-
bilities to ALS pathology, and the concept of ‘propagation’
includes non-contiguous spread.
To clarify how ALS progresses, we need to determine in ALS
patients whether single or multiple spinal and cortical lesions are
present in the early stages, and whether these lesions progress
contiguously or non-contiguously. Prospective and longitudinal
investigations with detailed electrophysiological and advanced
neuroimaging analyses are needed to address these questions. In
basic research, we need a cellular model for identifying the
transferred molecule and for dissecting the molecular mecha-
nism of cellular propagation, and an animal model for analysing
the spatiotemporal spread of ALS lesions.
Nonetheless, the hypothesis of propagation could have
important therapeutic implications. We expect that the mech-
anism of disease onset is different from that of progression, and
therefore therapy for the cause of disease onset will not neces-
sarily be enough to cure ALS patients who are already symp-
tomatic. The development of effective treatments will depend
on elucidation of the speciﬁc molecular mechanisms of
progression, and if focality is truly a feature of ALS, then ther-
apies could be applied regionally at early stages to suppress or
prevent progression and to spare the critical neurons that control
respiration.
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